Azelastine Hydrochloride

The H1 receptor, also known as the histamine H1 receptor, plays a crucial role in the human body. It is primarily found in smooth muscle cells, endothelial cells, and nerve cells. Activation of the H1 receptor by histamine leads to various physiological responses, including vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of sensory nerve endings. These responses are involved in allergic reactions, inflammation, and immune responses. Antagonists of the H1 receptor, commonly known as antihistamines, are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. Understanding the role of the H1 receptor is essential for developing effective treatments for allergic and inflammatory disorders. The analysis of the target H1 receptor reveals a competitive landscape with multiple companies actively developing drugs. GSK Plc, Sanofi, Pfizer Inc., Bayer AG, and Novartis AG are among the companies with the highest number of approved drugs or drugs in advanced stages of development. The indications with the most approved drugs include Common Cold, Rhinitis, Allergic, Urticaria, Pruritus, and Hypersensitivity. Small molecule drugs are the most rapidly progressing drug type, indicating intense competition in this area. China, the United States, and Japan are the countries with the highest number of approved drugs, with China showing significant progress in the development of drugs targeting the H1 receptor. Overall, the target H1 receptor presents opportunities for further research and development, particularly in indications with high unmet medical needs. How do they work?H1 receptor antagonists, also known as H1 blockers or antihistamines, are a class of drugs that block the action of histamine at the H1 receptor. Histamine is a chemical released by the body during an allergic reaction, causing symptoms such as itching, sneezing, runny nose, and watery eyes. H1 receptor antagonists work by binding to the H1 receptors on cells, preventing histamine from binding and exerting its effects. From a biomedical perspective, H1 receptor antagonists are commonly used to treat allergic conditions, such as hay fever (allergic rhinitis), hives (urticaria), and allergic conjunctivitis. They help alleviate symptoms by reducing the effects of histamine, thereby relieving itching, sneezing, and other allergic reactions. There are different generations of H1 receptor antagonists, each with varying degrees of sedative effects. First-generation antihistamines, such as diphenhydramine and chlorpheniramine, can cause drowsiness and are often used for their sedative properties in addition to their antihistamine effects. Second-generation antihistamines, such as cetirizine, loratadine, and fexofenadine, are less likely to cause sedation and are preferred for daytime use. In summary, H1 receptor antagonists are drugs that block the action of histamine at the H1 receptor, providing relief from allergic symptoms. They are commonly used in the treatment of various allergic conditions and come in different generations with varying sedative effects. List of H1 receptor AntagonistsThe currently marketed H1 receptor antagonists include: Olopatadine Hydrochloride/Mometasone Furoate MonohydrateChlorpheniramine Maleate/Codeine PhosphateDiphenhydramine Hydrochloride/Naproxen SodiumRecombinant interferon alfa-2b/LoratadineRupatadine FumarateAzelastine/mometasoneEbastine/Pseudoephedrine HydrochlorideAzelastine Hydrochloride/Fluticasone PropionateChlorpheniramine Maleate/Hydrocodone Bitartrate/Pseudoephedrine HydrochlorideAlcaftadineFor more information, please click on the image below. What are H1 receptor antagonists used for?H1 receptor antagonists are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release.  For more information, please click on the image below to log in and search. How to obtain the latest development progress of H1 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of H1 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

Bayer’s OTC antihistamine Astepro took the top spot, but new prescription meds from Big Pharma also had a strong showing. Pharmaceutical drugs made up half of the most-seen new brands by TV ad impressions for the first half of 2023 as the industry looks to boost awareness of its newest offerings. That’s according to a new report shared with Fierce Pharma Marketing by real-time ad tracker iSpot.TV. The report, which covered ad impressions for the first half of this year, found that pharma brands dominated the top 10 new brands with the highest ad impressions for TV airtime. In fact, pharma brands occupied five out of those spots including the top three positions. In at No. 1 was Bayer’s OTC antihistamine Astepro, with the German Big Pharma clearly capitalizing on the strong hay fever season this year. That drug saw 7.39 billion TV ad impressions, according to iSpot’s data, by far the most of all new brands, with NBC being its top network. At No. 2 was AbbVie's immunology drug Skyrizi, which recorded just over 6 billion TV ad impressions specifically for its Crohn's disease label. Additionally, NBC proved to be its largest network in terms of ad impressions. This year, Skyrizi is competing to have the highest ad spend among all prescription products. AbbVie is aiming to make up for the declining revenue it's experiencing from its aging blockbuster drug Humira. In third place is Bristol Myers Squibb’s newly approved plaque psoriasis med Sotyktu with 4.3 billion impressions in the first half of this year. ABC was its biggest network in terms of ad impressions. That dermatology med debuted at the Grammys earlier this year with the spot “Found It,” which focuses on two people who have cleared their skin and gained confidence thanks to Sotyktu, a once-a-day pill approved by the FDA last fall. The next Big Pharma drug comes in at eighth place with Eli Lilly’s blockbuster-in-waiting diabetes therapy Mounjaro, with just over 3 billion TV ad impressions and ABC as its largest network. Lilly launched a direct-to-consumer campaign this year for Mounjaro, which received FDA approval in May 2022. Since its advertisement launch in April, the therapy has consistently ranked among the top 10 pharmaceutical TV drug ad spenders. That could jump even more next year as Lilly is angling for the drug to nab a second approval in obesity, which could launch a major market battle with rival Novo Nordisk and its new obesity therapy Wegovy. Rounding off the pharma top five, and in ninth place overall, is AbbVie’s Skyrizi once again, but this time for its psoriatic arthritis indication, with 2.96 billion impressions and NBC as its top network.